Watertown, MA – Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, sold 17,184 shares on May 26-27, 2026, totaling approximately $1.37 million.
The sale occurred at prices between $78.36 and $82.08 per share. KYMR currently trades at $81.75, reflecting a 190% return over the past year.
Of the total, 4,054 shares were sold automatically to cover tax withholding. The remaining 13,130 were sold under a pre-arranged 10b5-1 trading plan adopted on December 10, 2025.
Following the sale, Chadwick directly owns 44,018 shares.
In recent news, Kymera reported strong Q1 2026 results: EPS of -$0.71 (beat estimate of -$0.88) and revenue of $34.36M (estimate $8.01M).
The company also presented Phase 1b data for KT-621 in atopic dermatitis at major conferences.
